×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
Overexpression of cyclooxygenase-2 in oral cancer increases lymph node metastasis and is associated with a poor prognosis.
28740192 2017
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
GeneticVariation
BEFREE
Several electronic databases were searched for published studies using combinations of keywords related to COX-2 gene polymorphisms and oral cancer .
25977924 2015
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
Biomarker
BEFREE
Hypermethylation of E-cadherin and COX-2 was observed in 36% and 22% of oral cancer samples, respectively.
23250779 2012
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
In a previous study, we demonstrated that cyclooxygenase-2 (COX-2 ) is overexpressed in Korean patients having oral cancer .
19910795 2010
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
Biomarker
BEFREE
PGE2 production in oral cancer cell lines is COX-2 -dependent.
19278989 2009
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
PosttranslationalModification
BEFREE
Overexpression of the cyclooxygenase-2 gene (COX-2 ) is observed frequently in OPLs and oral cancers, suggesting that this gene may play an important role in the progression of oral cancer .
19197984 2009
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
GeneticVariation
BEFREE
Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer .
18922923 2008
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
COX-2 expression in oral cancer was found to be independent of grade of tumor and stage of disease.18356024 2008
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
We measured COX-1 and COX-2 m-RNA expression in samples of both oral cancer and matched oral mucosa from 22 patients by RealTime RT-PCR; clinic pathological data (grading, TNM staging, inflammation, follow-up) of all patients were available for statistical evaluation.
17624243 2007
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2 .
17595767 2007
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
In conclusion, this study demonstrates correlation between over expression of NF-kappaB and COX-2 in early precancerous stages of development of oral cancer and sustained elevation down the tumorigenic pathway, underscoring their potential as targets for early intervention.
17354234 2007
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
15756036 2005
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
Biomarker
BEFREE
Molecular targeting of COX-2 , PGE(2) synthase, or PGE(2) receptors may be useful as a chemopreventive or therapeutic strategy for oral cancer .
12738747 2003
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
AlteredExpression
BEFREE
COX-2 expression was correlated to DNA content as a genetic risk marker of oral cancer .12747975 2003
×
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
Lip and Oral Cavity Carcinoma
0.100
GeneticVariation
BEFREE
These data strongly indicate that COX-2 inhibitors (coxibs) should be investigated as chemopreventive agents in patients identified to be at high risk of developing oral cancer .
12542827 2003